Linzagolix: an oral gonadotropin-releasing hormone receptor antagonist treatment for uterine fibroid-associated heavy menstrual bleeding

Affiliations

¹ Amsterdam Reproduction and Development Research Institute, Amsterdam, Netherlands.
² Department of Obstetrics and Gynaecology, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam Medical Centers, Amsterdam 1105 AZ, Netherlands. Electronic address: j.huirne@amsterdamumc.nl.

Comment

Maria E de Lange et al. Lancet. 2022.

. 2022 Sep 17;400(10356):866-867.

doi: 10.1016/S0140-6736(22)01781-0.

¹ Amsterdam Reproduction and Development Research Institute, Amsterdam, Netherlands.
² Department of Obstetrics and Gynaecology, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam Medical Centers, Amsterdam 1105 AZ, Netherlands. Electronic address: j.huirne@amsterdamumc.nl.

No abstract available

Conflict of interest statement

We declare no competing interests.

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
Donnez J, Taylor HS, Stewart EA, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland JP, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Donnez J, et al. Lancet. 2022 Sep 17;400(10356):896-907. doi: 10.1016/S0140-6736(22)01475-1. Lancet. 2022. PMID: 36116480 Clinical Trial.